Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACIU NASDAQ:EDSA NASDAQ:NAGE NASDAQ:SIGA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$2.51$2.63$1.94▼$4.00$255.45M1.57315,568 shs364,528 shsEDSAEdesa Biotech$7.50$9.52$0.72▼$20.32$66.69M1.03201,431 shs68,074 shsNAGENiagen Bioscience$3.43$3.79$3.17▼$12.74$273.18M2.09660,725 shs464,480 shsSIGASiga Technologies$3.86$4.37$3.56▼$9.62$276.86M0.96573,494 shs544,961 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune0.00%-1.38%+4.80%-9.06%+24.26%EDSAEdesa Biotech0.00%-8.42%+9.33%+22.15%+267.65%NAGENiagen Bioscience0.00%+0.29%-0.29%-21.69%-72.73%SIGASiga Technologies0.00%-1.53%-10.02%-26.34%-42.22%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$2.51$2.63$1.94▼$4.00$255.45M1.57315,568 shs364,528 shsEDSAEdesa Biotech$7.50$9.52$0.72▼$20.32$66.69M1.03201,431 shs68,074 shsNAGENiagen Bioscience$3.43$3.79$3.17▼$12.74$273.18M2.09660,725 shs464,480 shsSIGASiga Technologies$3.86$4.37$3.56▼$9.62$276.86M0.96573,494 shs544,961 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune0.00%-1.38%+4.80%-9.06%+24.26%EDSAEdesa Biotech0.00%-8.42%+9.33%+22.15%+267.65%NAGENiagen Bioscience0.00%+0.29%-0.29%-21.69%-72.73%SIGASiga Technologies0.00%-1.53%-10.02%-26.34%-42.22%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACIUAC Immune 2.40Hold$7.50198.80% UpsideEDSAEdesa Biotech 2.67Moderate Buy$5.00-33.33% DownsideNAGENiagen Bioscience 2.67Moderate Buy$10.50206.12% UpsideSIGASiga Technologies 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest EDSA, ACIU, NAGE, and SIGA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2026SIGASiga Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)7/1/2026ACIUAC Immune HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/1/2026NAGENiagen Bioscience HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/29/2026EDSAEdesa Biotech Brookline Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/24/2026EDSAEdesa Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/15/2026SIGASiga Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)5/28/2026SIGASiga Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/11/2026SIGASiga Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)5/11/2026NAGENiagen Bioscience HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $11.005/8/2026ACIUAC Immune Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/5/2026NAGENiagen Bioscience Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$13.00 ➝ $10.00(Data available from 7/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACIUAC Immune$4.31M59.27N/AN/A$0.54 per share4.65EDSAEdesa BiotechN/AN/AN/AN/A$0.45 per shareN/ANAGENiagen Bioscience$129.42M2.11$0.20 per share16.91$0.96 per share3.57SIGASiga Technologies$94.57M2.93$0.33 per share11.59$2.78 per share1.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACIUAC Immune-$85.03M-$0.82N/A14.76N/A-1,788.02%-125.26%-40.85%8/4/2026 (Estimated)EDSAEdesa Biotech-$7.19M-$1.34N/AN/AN/AN/A-286.52%-75.36%8/14/2026 (Estimated)NAGENiagen Bioscience$17.38M$0.2116.3311.43N/A14.29%22.68%16.23%N/ASIGASiga Technologies$23.28M$0.2714.30N/AN/A21.58%10.60%8.94%8/4/2026 (Estimated)Latest EDSA, ACIU, NAGE, and SIGA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q2 2026EDSAEdesa Biotech-$0.24-$0.49-$0.25-$0.49$0.05 millionN/A5/7/2026Q1 2026SIGASiga TechnologiesN/A-$0.05N/A-$0.05N/A$6.24 million5/6/2026Q1 2026NAGENiagen Bioscience$0.06$0.07+$0.01$0.07N/A$31.47 million4/30/2026Q1 2026ACIUAC Immune-$0.20-$0.19+$0.01-$0.19$0.33 million$1.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACIUAC ImmuneN/AN/AN/AN/AN/AEDSAEdesa BiotechN/AN/AN/AN/AN/ANAGENiagen BioscienceN/AN/AN/AN/AN/ASIGASiga TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACIUAC Immune0.110.871.02EDSAEdesa BiotechN/A4.764.76NAGENiagen BioscienceN/A4.613.55SIGASiga TechnologiesN/A3.252.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACIUAC Immune51.36%EDSAEdesa Biotech5.50%NAGENiagen Bioscience15.41%SIGASiga Technologies55.40%Insider OwnershipCompanyInsider OwnershipACIUAC Immune4.60%EDSAEdesa Biotech24.40%NAGENiagen Bioscience10.00%SIGASiga Technologies2.73%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACIUAC Immune140101.77 million97.09 millionOptionableEDSAEdesa Biotech208.89 million6.72 millionNot OptionableNAGENiagen Bioscience12079.64 million71.68 millionN/ASIGASiga Technologies4071.72 million69.77 millionOptionableEDSA, ACIU, NAGE, and SIGA HeadlinesRecent News About These CompaniesIs SIGA Technologies’ (SIGA) Index Shift and ESOP Shelf Registration Reframing Its Defensive Identity?June 30, 2026 | finance.yahoo.comDiscovering SIGA Technologies And 2 Other Compelling Penny StocksMay 22, 2026 | finance.yahoo.comSIGA Technologies (SIGA) Is Down 9.9% After Q1 Revenue Miss And Sharper Net Loss - What's ChangedMay 15, 2026 | finance.yahoo.comSome Investors May Be Willing To Look Past SIGA Technologies' (NASDAQ:SIGA) Soft EarningsMay 14, 2026 | finance.yahoo.comSIGA (SIGA) Q1 2026 Earnings Call TranscriptMay 8, 2026 | fool.comSIGA expects Q2 delivery of approximately $13M of oral TPOXX while targeting an FDA PEP submission in the next 12 monthsMay 8, 2026 | msn.comSIGA Technologies, Inc. Q1 2026 Earnings Call SummaryMay 8, 2026 | finance.yahoo.comSIGA Technologies, Inc. (SIGA) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comSIGA Reports Financial Results for Three Months Ended March 31, 2026 and Provides Business UpdateMay 7, 2026 | globenewswire.comSIGA to Host Business Update Call on May 7, 2026, Following Release of First-Quarter 2026 Financial ResultsApril 30, 2026 | globenewswire.comWhy SIGA Technologies, Inc.’s (SIGA) Stock Is Up 7.36%March 28, 2026 | aaii.comASIGA mpox therapy no longer recommended in EUMarch 27, 2026 | msn.comSiga Technologies Declares Special Dividend of 60 CentsMarch 26, 2026 | marketwatch.comSIGA Declares Special Cash Dividend of $0.60 Per ShareMarch 26, 2026 | globenewswire.comSiga Technologies (NASDAQ:SIGA) Options Surge Hits Nasdaq 100 IndexMarch 19, 2026 | kalkinemedia.comKMpox Is on the Rise. 3 Vaccine Stocks Worth a Second Look.March 17, 2026 | barrons.comA Look At SIGA Technologies (SIGA) Valuation After Weaker 2025 Earnings And Ongoing TPOXX Contract ProgressMarch 15, 2026 | finance.yahoo.comSIGA Technologies (SIGA) Is Down 9.3% After Mixed 2025 Results and New Biodefense Contract WinsMarch 15, 2026 | finance.yahoo.comSIGA Technologies Eyes TPOXX Growth As New Contracts Meet Lumpy RevenueMarch 14, 2026 | finance.yahoo.comSIGA Technologies Inc (SIGA) Q4 2025 Earnings Call Highlights: Strong Financial Performance and ...March 11, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesDividend Increases: From Over 10% Yields to Over 10% Dividend GrowthBy Leo Miller | June 24, 2026Navitas: NVIDIA’s AI Power Broker?By Jeffrey Neal Johnson | June 5, 20263 Non-Pharma Firms That Could Benefit From the GLP-1 TrendBy Nathan Reiff | June 20, 20263 Waste Stocks Turning AI Investments into GrowthBy Chris Markoch | June 27, 2026The J.M. Smucker Company’s Dividend: Too Sweet to Ignore?By Thomas Hughes | June 9, 2026EDSA, ACIU, NAGE, and SIGA Company DescriptionsAC Immune NASDAQ:ACIU$2.51 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$2.37 -0.14 (-5.54%) As of 07/2/2026 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.Edesa Biotech NASDAQ:EDSA$7.50 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$7.44 -0.06 (-0.80%) As of 07/2/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.Niagen Bioscience NASDAQ:NAGE$3.43 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$3.42 -0.01 (-0.15%) As of 07/2/2026 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.Siga Technologies NASDAQ:SIGA$3.86 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$4.04 +0.19 (+4.79%) As of 07/2/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Shorting the Grid: Bloom Energy’s $25B AI Power Play Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
